Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal upside

Trevi Therapeutics attracts attention with double?digit short interest while several Wall Street houses see further upside for the biotech stock. What stands behind the figures – and what should US investors know about the niche rare?disease player?

Trevi Therapeutics is back on the radar of active traders as fresh data show elevated short interest alongside upbeat analyst expectations for the Nasdaq?listed biotech stock. As of April 30, 2026, around 13.18% of the public float was sold short, according to data compiled by MarketBeat, while a group of Wall Street analysts projects significantly higher prices over the next twelve months, as summarized by MarketBeat on May 15, 2026.MarketBeat as of 04/30/2026MarketBeat as of 05/15/2026

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Trevi Therapeutics Inc.
• Sector/industry: Biotechnology, rare diseases
• Headquarters/country: New Haven, United States
• Core markets: North America and Europe for specialty CNS and rare?disease therapies
• Key revenue drivers: Development and potential commercialization of pruritus and central nervous system therapies
• Home exchange/listing venue: Nasdaq (ticker: TRVI)
• Trading currency: US dollar (USD)

Trevi Therapeutics: core business model

Trevi Therapeutics focuses on developing therapies for conditions that cause significant discomfort and impaired quality of life, particularly in rare or underserved indications. The company’s strategy is to target central nervous system pathways thought to drive chronic pruritus and related symptoms, positioning itself in niche segments where few approved treatments currently exist, according to its corporate profile as of March 2026.Trevi corporate information as of 03/2026

The pipeline is centered on investigational therapies aimed at reducing severe itch and associated burdens in patient populations such as those with chronic kidney disease–associated pruritus or other systemic illnesses. By concentrating on indications with high unmet need and limited competition, Trevi Therapeutics seeks to create a focused portfolio with potentially strong pricing power if clinical trials are successful and regulatory approvals are granted, as described in company materials updated in early 2026.Trevi investor information as of 03/2026

The business model in biotechnology typically involves substantial upfront research and development spending over many years before commercial revenues are realized. Trevi Therapeutics therefore relies on equity financing and, where available, collaboration income or milestone payments to fund its pipeline. This pattern means that news on clinical trial progress, regulatory milestones or capital measures can have a pronounced impact on the share price, particularly for US investors following small and mid?cap biotech names on Nasdaq.

Main revenue and product drivers for Trevi Therapeutics

At this stage, Trevi Therapeutics is still primarily a development?stage company, meaning that near?term revenue expectations hinge on the successful advancement of key assets through late?stage clinical trials. The lead program focuses on treating severe pruritus in patient populations where itch significantly reduces sleep, emotional well?being and daily functioning, which the company has highlighted in presentations to investors during 2025 and 2026.Trevi investor presentation as of 2025/2026

If pivotal studies deliver positive data and regulators in major markets such as the US Food and Drug Administration and the European Medicines Agency eventually grant approval, Trevi Therapeutics could transition from a pure R&D story to a commercial operation. In that scenario, the initial revenue driver would likely be the first approved product in a narrowly defined indication with high unmet medical need, followed by potential label expansions and geographic roll?outs that broaden the addressable market over time.

Beyond the lead indication, Trevi Therapeutics is exploring additional uses for its therapeutic approach, which may involve other forms of chronic pruritus or central nervous system–mediated conditions. Each of these programs represents a potential incremental value driver, but also introduces clinical, regulatory and financing risks. For US investors, this pipeline structure means that company?specific catalysts, such as top?line trial results, advisory committee meetings or regulatory filing acceptances, can quickly change the medium?term revenue outlook.

Short interest: elevated positioning among bearish traders

Short?interest statistics provide a snapshot of how many shares market participants have borrowed and sold in the expectation of future price declines. As of April 30, 2026, traders had sold 15,291,551 Trevi Therapeutics shares short, equivalent to around 13.18% of the public float, according to MarketBeat’s compilation of exchange data.MarketBeat as of 04/30/2026

The same data set shows that this figure represented a decrease of approximately 5.25% compared with the prior reporting period, signaling that some short sellers recently trimmed their positions. The short?interest ratio, also known as days to cover, stood at 6.7 based on an average daily trading volume of about 1.50 million shares at the time of the report, meaning it would theoretically take several trading days for all short positions to be covered if buying pressure materialized, according to MarketBeat’s calculations published in late April 2026.MarketBeat as of 04/30/2026

For a relatively small biotech company, double?digit short interest is not unusual, as investors may use short positions to hedge sector exposure or express skepticism over clinical and financing risks. However, such positioning can also amplify volatility if unexpected positive news arrives and short sellers are forced to buy back shares quickly. US retail investors following Trevi Therapeutics should therefore be aware that sentiment in the derivatives and lending markets can influence the share price independently of day?to?day fundamental news.

Analyst expectations: consensus points to higher share price

While short interest remains notable, several Wall Street analysts tracking Trevi Therapeutics are more optimistic over a twelve?month horizon. According to MarketBeat’s summary of research coverage updated on May 15, 2026, twelve equities research analysts have issued 12?month price targets for the stock. Their average target stands at 22.90 USD, with a high estimate of 30.00 USD and a low estimate of 16.00 USD.MarketBeat as of 05/15/2026

Based on the same dataset, the average target implies a potential upside of roughly 70.51% compared with a reference price of 13.43 USD reported by MarketBeat in mid?May 2026. The platform also notes that, on balance, the analysts currently covering Trevi Therapeutics express a "buy" stance on the shares, reflecting their interpretation of the company’s risk?reward profile at this stage of its pipeline development, according to the consensus overview published on May 15, 2026.MarketBeat as of 05/15/2026

These figures do not guarantee future performance and should be interpreted as indicative of prevailing sentiment among a specific group of covering institutions rather than as a uniform forecast. For private investors in the US and Germany, the dispersion between high and low targets illustrates how differently market professionals assess the probabilities of clinical success, regulatory approval and capital?market access for Trevi Therapeutics over the coming years.

Why Trevi Therapeutics matters for US investors

Trevi Therapeutics is part of a broader cohort of specialized biotech companies that populate the Nasdaq and serve as vehicles for investors to gain exposure to medical innovation. For US investors, the stock offers focused exposure to rare?disease and symptom?management therapies, which can sometimes generate attractive pricing and margin dynamics if they successfully reach the market. This is one reason why Wall Street continues to devote research resources to the name despite its relatively modest market capitalization.

At the same time, Trevi Therapeutics faces many of the structural challenges typical of development?stage biotechs, including the need to fund multi?year clinical programs and manage regulatory interactions in multiple jurisdictions. Shareholders must navigate potential dilution from equity raises, variability in trial timelines and the binary nature of key data read?outs. These dynamics are particularly relevant for US?based portfolios that already hold a concentration of healthcare innovators and are sensitive to sector?specific volatility.

For cross?border investors in Germany and elsewhere in Europe, Trevi Therapeutics also highlights how transatlantic biotech interest often centers on US?listed names. Liquidity on Nasdaq, coverage by North American banks and the depth of the US healthcare market can make such stocks attractive, though currency risk and different regulatory frameworks must also be taken into account when comparing them with locally listed biotech peers.

Conclusion

Trevi Therapeutics sits at the intersection of high medical need, significant clinical and regulatory risk, and pronounced market expectations. Elevated short interest shows that a meaningful cohort of traders is positioning for setbacks or volatility, while the current analyst consensus compiled by MarketBeat points to sizeable upside if the development plan proceeds as hoped. For investors in the US and abroad, the stock therefore represents a focused bet on the company’s ability to advance its rare?disease pipeline and secure funding on acceptable terms, with outcomes likely to be driven more by trial data and regulatory decisions than by short?term macroeconomic trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.